Back to top
more

Pacific Biosciences of California (PACB)

(Real Time Quote from BATS)

$1.32 USD

1.32
2,242,214

-0.01 (-0.75%)

Updated Aug 4, 2025 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Beyond analysts' top-and-bottom-line estimates for Pacific Biosciences (PACB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

Zacks Equity Research

Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

Pacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close.

Zacks Equity Research

Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Pacific Biosciences of California (PACB) reached $1.39 at the closing of the latest trading day, reflecting a -6.71% change compared to its last close.

Zacks Equity Research

Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close.

Zacks Equity Research

Here's Why You Should Add PacBio Stock to Your Portfolio Now

by Zacks Equity Research

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.

Zacks Equity Research

Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.24, representing a -3.88% change from its previous close.

Zacks Equity Research

Why Is Steris (STE) Down 1.8% Since Last Earnings Report?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.

Zacks Equity Research

Here's Why You Should Add PacBio Stock to Your Portfolio Now

by Zacks Equity Research

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.

Zacks Equity Research

All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy

by Zacks Equity Research

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

PacBio Stock Slips Despite New China Distribution Deal With Haorui

by Zacks Equity Research

PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.

Zacks Equity Research

PACB Stock May Rise Following the Deal With Chulalongkorn University

by Zacks Equity Research

PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.

Zacks Equity Research

PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates

by Zacks Equity Research

Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.

Zacks Equity Research

Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 21.05% and 6.15%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacific Biosciences of California (PACB) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.11, marking a -1.77% move from the previous day.

Zacks Equity Research

Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.17, marking no change from the previous day.

Zacks Equity Research

Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

Pacific Biosciences of California (PACB) reachead $1.26 at the closing of the latest trading day, reflecting a +0.8% change compared to its last close.

Zacks Equity Research

Here's Why You Should Retain PacBio Stock in Your Portfolio Now

by Zacks Equity Research

PACB continues to deliver growth from its unique technologies amid macroeconomic concerns.

Zacks Equity Research

Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.22, denoting a +1.67% change from the preceding trading day.

Zacks Equity Research

PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall

by Zacks Equity Research

Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments.

Zacks Equity Research

Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.44, representing a -1.37% change from its previous close.